Institutional Investments Rise
Geode Capital and Other Major Investors Boost Stakes in U.S. Companies Amid Varied Analyst Views
Geode Capital Management disclosed stake increases across several large U.S. companies, including adding 203,200 shares of Stanley Black & Decker and raising its holdings worth about $300 million, alongside other major institutional investors that also increased positions. In BXP, Geode lifted its stake by about 1.3% to roughly 4.27 million shares, while other investors expanded more aggressively and analyst coverage included a Citigroup move toward a lower target and a neutral stance. For Acuity, Geode increased its holdings by about 3.8% to about 570,000 shares, and analysts showed a split view with rating changes and multiple price-target reductions from firms such as Wells Fargo, Goldman Sachs, and Robert W. Baird. In HealthEquity, Geode also added shares, with separate filings showing a small increase in its stake and the position valued around $200 million. Other institutional owners remain dominant in both HealthEquity and these other names, and several analysts have recently adjusted targets—such as Deutsche Bank raising its outlook for HealthEquity—suggesting investors are actively repricing expectations even as Geode steadily increases exposure.
Key Points
In Stanley Black & Decker (SWK), Ameriprise Financial sharply increased its stake—boosting holdings by 49.5% (adding 1,450,170 shares) to 4,379,653 shares, valued at about $325.5 million at the end of the quarter.
For BXP, alongside Geode’s 1.3% increase, Invesco expanded its position by 44.9% to 3,896,978 shares, Daiwa Securities increased by 76.8% to 2,012,057 shares, and Russell Investments more than doubled (+145.5%) to 663,445 shares—showing a broader pattern of aggressive accumulation by other funds.
In Acuity (AYI) analyst commentary, Weiss Ratings downgraded the stock from a “hold (c+)” to a “hold (c)” (May 6), while Wall Street Zen raised the shares from “hold” to “buy” (April 12). The combination underscores the sharper dispersion of views beyond the price-target cuts mentioned in the summary.
For HealthEquity (HQY), Deutsche Bank increased its price objective from $120 to $128 and assigned a “buy” rating (March 19), adding specificity to the note that investors are repricing expectations upward.
Also on HealthEquity, RBC boosted its price target from $100 to $108 and reiterated an “outperform” rating—another indicator of mixed-but-improving sell-side sentiment for HQY.
Sentiment
Mostly PositivePublishers
17
Articles
15
Reach
32
